1.
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who pr...
by Ou, Sai-Hong Ignatius
Lung cancer (Amsterdam, Netherlands), 2017, Vol.108, p.228-231
2.
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers
by Tiseo, Marcello
Lung cancer (Amsterdam, Netherlands), 2009, Vol.67 (3), p.355-360
3.
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who pr...
by Ou, Sai-Hong Ignatius
Lung cancer (Amsterdam, Netherlands), 2017, Vol.108, p.228-231
4.
Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance
by Massarelli, Erminia
Lung cancer (Amsterdam, Netherlands), 2013, Vol.80 (3), p.235-241
5.
Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer
by Nazha, Bassel
Future oncology (London, England), 2021, Vol.17 (8), p.965-977
6.
Sequential afatinib and osimertinib in patients with
Future oncology (London, England), 2020, Vol.16 (34), p.2799-2808
7.
Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial
by Planchard, David
The lancet oncology, 2017, Vol.18 (10), p.1307-1316
8.
USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma
by Zhang, Huijuan
Cancer letters, 2018, Vol.433, p.186-198
9.
Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies
by Tan, Fenlai
Lung cancer (Amsterdam, Netherlands), 2011, Vol.76 (2), p.177-182
10.
How can better identification of T790M help to inform treatment sequencing decisions in
Future oncology (London, England), 2019, Vol.15 (25), p.2895-2898
11.
12.
Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer
by Yoh, Kiyotaka
Current medical research and opinion, 2020, Vol.36 (10), p.1667-1675
13.
Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas
by Projetti, Fabrice, MD
Human pathology, 2013, Vol.44 (10), p.2116-2125
14.
Therapies after first-line afatinib in patients with EGFR m + NSCLC in Japan: retrospective analysis of LUX-Lung 3
by Yoshioka, Hiroshige
Future oncology (London, England), 2020, Vol.16 (4), p.49-60
15.
Comparing the Effects of Afatinib with Gefitinib or Erlotinib in Patients with Advanced-Stage Lung Adenocarcinoma Harboring Non-classical Epidermal Growth Factor Receptor Mutations
by Shen, Yi-Cheng
Lung cancer (Amsterdam, Netherlands), 2017, Vol.110, p.56-62
16.
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for
Future oncology (London, England), 2021, Vol.17 (31), p.4045-4055
17.
EGFR-TKI-induced HSP70 degradation and BER suppression facilitate the occurrence of the EGFR T790M resistant mutation in lung cancer cells
by Cao, Xiang Xiang
Cancer letters, 2018, Vol.424, p.84-96
18.
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation
by Park, S.J
Lung cancer (Amsterdam, Netherlands), 2012, Vol.77 (3), p.556-560
19.
Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer
by Kimura, Hideharu
Lung cancer (Amsterdam, Netherlands), 2014, Vol.83 (3), p.329-333
